{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:29:23Z","timestamp":1772886563180,"version":"3.50.1"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NO FUNDING"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0237365","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T17:22:42Z","timestamp":1603128162000},"page":"e0237365","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment duration of complicated urinary tract infections by extended-spectrum beta-lactamases producing enterobacterales"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4908-2866","authenticated-orcid":true,"given":"Judith","family":"\u00c1lvarez Otero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Lamas Ferreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Sanjurjo Rivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Maroto Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Gonz\u00e1lez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Enr\u00edquez de Salamanca Holzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cavero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Rodr\u00edguez Conde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Fern\u00e1ndez Soneira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"de la Fuente Aguado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"pone.0237365.ref001","unstructured":"http:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/."},{"key":"pone.0237365.ref002","unstructured":"Surveillance of antimicrobial resistance in Europe 2018. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/surveillance-antimicrobial-resistance-Europe-2018.pdf"},{"key":"pone.0237365.ref003","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijid.2019.06.017","article-title":"National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States","volume":"85","author":"V Gupta","year":"2019","journal-title":"Int J Infect Dis"},{"key":"pone.0237365.ref004","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1186\/s12879-019-4387-3","article-title":"Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013\u20132017","volume":"19","author":"V Gupta","year":"2019","journal-title":"BMC Infect Dis"},{"key":"pone.0237365.ref005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/phar.2118","article-title":"Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials","volume":"38","author":"AM Hanretty","year":"2018","journal-title":"Pharmacotherapy"},{"key":"pone.0237365.ref006","doi-asserted-by":"crossref","first-page":"336","DOI":"10.12788\/jhm.2905","article-title":"Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis","volume":"13","author":"S Royer","year":"2018","journal-title":"J Hosp Med"},{"key":"pone.0237365.ref007","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dkt177","article-title":"Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection\u20147 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"N Eliakim-Raz","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"pone.0237365.ref008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciq257","article-title":"Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"K Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0237365.ref009","unstructured":"US Food and Drug Administration (FDA) Complicated urinary tract infections: developing drugs for treatment: guidance for industry. FDA website. https:\/\/www.fda.gov\/media\/71313\/download. June 2018."},{"key":"pone.0237365.ref010","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"T Sandberg","year":"2012","journal-title":"Lancet"},{"key":"pone.0237365.ref011","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","article-title":"Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women","volume":"1","author":"C van Nieuwkoop","year":"2017","journal-title":"BMC Med"},{"key":"pone.0237365.ref012","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10096-017-2951-6","article-title":"Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial","volume":"36","author":"A Dinh","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"pone.0237365.ref013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"J Peterson","year":"2008","journal-title":"Urology"},{"key":"pone.0237365.ref014","doi-asserted-by":"crossref","first-page":"ofz216","DOI":"10.1093\/ofid\/ofz216","article-title":"No Clinical Benefit to Treating Male Urinary Tract Infection Longer Than Seven Days: An Outpatient Database Study","volume":"6","author":"GJ Germanos","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"pone.0237365.ref015","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/jac\/dkq152","article-title":"Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum- beta-lactamase-producing Gram-negative organisms","volume":"65","author":"R Bazaz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"pone.0237365.ref016","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","article-title":"Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing escherichia coli-related complicated lower urinary tract infection","volume":"22","author":"S Senol","year":"2010","journal-title":"J Chemother"},{"key":"pone.0237365.ref017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","article-title":"Comparison of fosfomycin to ertapenem for outpatient or stepdown therapy of extended-spectrum \u03b2-lactamase urinary tract infections","volume":"48","author":"MP Veve","year":"2016","journal-title":"Int J Antimicrob Agents"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T22:28:18Z","timestamp":1669242498000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237365"}},"subtitle":[],"editor":[{"given":"Martina","family":"Crivellari","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0237365","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]}}}